Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Milvexian in Renal Impairment
NCT03196206Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of milvexian in thrombosis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 5 days, Area under the concentration-time curve from time zero to last quantifiable concentration up to 5 days and 1 more. Started Jul 2017; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03196206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196206.